BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 7, 2006
View Archived Issues
DNA Strand Segregation Joins List Of Nonrandom Processes
Read More
MannKind’s Inhaled Insulin In Phase III Efficacy Studies
Read More
Clinic Roundup
Read More
Other News To Note
Read More
Infinity, Novartis In $400M Deal For Inhibitors Of Bcl-2
Tackling a family of proteins linked to cancer but long considered undruggable, Infinity Pharmaceuticals Inc. and Novartis AG signed a global development and commercialization deal potentially worth more than $400 million. (BioWorld Today)
Read More
Heading To Clinic, Nereus Adds $18.3M To Series D
Read More